Target/Pathway Enrichment Report

Mapping Details for your submissionhelp

# Active Inactive
Your Submission 2051 149087
Mapped to Target 2057 149087
Mapped to Reactome 2057 149087
Mapped to GO 2057 149087

Table 1. Target/MultiTarget Enrichment help

View Full Report

# TARGET/MULTI-TARGET Odds Ratio p-value kA size
Active
kB size
InActive
1 gene: TLR9 inhibitor (gi:194068499, assay: 540250)
22.59 6.94e-12 14 2057 38 126131
2 gene: APOBEC3F inhibitor (gi:22907044, assay: 651814)
20.22 1.43e-26 32 2057 97 126131
3 gene: GALR2 antagonist (gi:6016094, assay: 866)
18.58 1.49e-07 10 2057 33 126131
4 gene: APOBEC3G inhibitor (gi:13399304, assay: 651812)
17.21 1.16e-24 32 2057 114 126131
5 gi:18418623 inhibitor (assay: 720536)
14.63 1.12e-14 21 2057 88 126131

Table 2. Pathway Enrichment help

View Full Report

# GO Term Odds Ratio p-value kA size
Active
kB size
InActive
1 (interactor) Unfolded Protein Response (UPR) 7.98 4.35e-05 11 1300 86 81144
2 (agonist) Platelet Aggregation (Plug Formation) 5.77 0.0027 10 1300 108 81144
3 (inhibitor) activated TAK1 mediates p38 MAPK activation 4.42 1.36e-27 90 1300 1269 81144
4 (inhibitor) BMAL1:CLOCK,NPAS2 activates circadian gene expression 4.29 1.43e-08 31 1300 450 81144
5 (inhibitor) JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 4.07 1.91e-25 91 1300 1393 81144

Table 3. GO term Enrichment help

View Full Report

# GO Term Odds Ratio p-value kA size
Active
kB size
InActive
1 (inhibitor) defense response to Gram-negative bacterium 10.05 4.48e-11 20 1421 129 92118
2 (interactor) fatty acid biosynthetic process 9.84 3.62e-06 12 1421 79 92118
3 (interactor) metallopeptidase activity 9.69 1.89e-08 16 1421 107 92118
4 (interactor) core promoter binding 9.38 2.33e-05 11 1421 76 92118
5 (antagonist) digestion 9.17 1.54e-07 15 1421 106 92118